References
- Dole VP , NyswanderM. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA193 , 646–650 (1965).
- Bart G . Maintenance medication for opiate addiction: the foundation of recovery. J. Addict. Dis.31(3) , 207–225 (2012).
- Veilleux JC , ColvinPJ, AndersonJ, YorkC, HeinzAJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin. Psychol. Rev.30(2) , 155–166 (2010).
- Torrens M , FonsecaF, CastilloC, Domingo-SalvanyA. Methadone maintenance treatment in Spain: the success of a harm reduction approach. Bull. World Health Organ.91(2) , 136–141 (2013).
- Crettol S , DeglonJJ, BessonJ et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther.80(6) , 668–681 (2006).
- Fonseca F , de la Torre R, Díaz L et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS ONE6(5) , e19527 (2011).
- Fonseca F , Martin-SantosR, RoigJ, TorrensM. Étude pharmacogenetique de la reponse au traitement a la methadone: pharmacogenetics of methadone treatment response. Courier des Addictions15(1) , 10–15 (2013).
- Ansermot N , AlbayrakO, SchläpferJ et al. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. Arch. Intern. Med. 170(6) , 529–536 (2010).
- Fonseca F , GratacòsM, EscaramísG et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol. Diagn. Ther. 14(3) , 171–178 (2010).
- Levran O , PelesE, RandesiM et al. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics 14(7) , 755–768 (2013).
- Oneda B , CrettolS, BochudM et al. β-arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 11(4) , 258–266 (2010).
- Kreek MJ , LevranO, ReedB, SchlussmanSD, ZhouY, ButelmanER. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J. Clin. Invest.122(10) , 3387–3393 (2012).
- Hajj A , KhabbazL, LaplancheJL, Peoc‘hK. Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics14(5) , 575–585 (2013).
- Koob GF , VolkowND. Neurocircuitry of addiction. Neuropsychopharmacology35(1) , 217–238 (2010).
- Addolorato G , LeggioL, HopfFW, DianaM, BonciA. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology37(1) , 163–177 (2012).
- Lüscher C , MalenkaRC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron69(4) , 650–663 (2011).
- Tyacke RJ , Lingford-HughesA, ReedLJ, NuttDJ. GABAB receptors in addiction and its treatment. Adv. Pharmacol.58 , 373–396 (2010).
- Nutt D , Lingford-HughesA. Addiction: the clinical interface. Br. J. Pharmacol.154(2) , 397–405 (2008).
- Kim KJ , PearlPL, JensenK et al. Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance. Antioxid. Redox Signal. 15(3) , 691–718 (2011).
- Blasi P , BoylPP, LeddaM et al. Structure of human succinic semialdehyde dehydrogenase gene: identification of promoter region and alternatively processed isoforms. Mol. Genet. Metab. 76(4) , 348–362 (2002).
- Malaspina P , PickloMJ, JakobsC, SneadOC, GibsonKM. Comparative genomics of aldehyde dehydrogenase 5a1 (succinate semialdehyde dehydrogenase) and accumulation of gamma-hydroxybutyrate associated with its deficiency. Hum. Genomics3(2) , 106–120 (2009).
- Galloway GP , Frederick-OsborneSL, SeymourR, ContiniSE, SmithDE. Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol20(3) , 263–269 (2000).
- Oliveto A , GentryWB, PruzinskyR et al. Behavioral effects of gamma-hydroxybutyrate in humans. Behav. Pharmacol. 21(4) , 332–342 (2010).
- Keating GM . Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin. Drug Investig.34(1) , 63–80 (2014).
- Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N. Engl. J. Med.352(26) , 2721–2732 (2005).
- Szabo ST , GoldMS, GoldbergerBA, BlierP. Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biol. Psychiatry55(9) , 934–939 (2004).
- Maldonado C , Rodríguez-AriasM, AguilarMA, MiñarroJ. GHB ameliorates naloxone-induced conditioned place aversion and physical aspects of morphine withdrawal in mice. Psychopharmacology (Berl.).177(1–2) , 130–140 (2004).
- Akaboshi S , HogemaBM, NovellettoA et al. Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum. Mutat. 22(6) , 442–450 (2003).
- Fonseca F , GratacòsM, EscaramísG et al. ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. Eur. Neuropsychopharmacol.24(3) , 420–424 (2014).
- Abanades S , FarreM, SeguraM et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann. NY Acad. Sci. 1074 , 559–576 (2006).
- Plomin R , TuricDM, HillL et al. A functional polymorphism in the succinate-semialdehyde dehydrogenase (aldehyde dehydrogenase 5 family, member A1) gene is associated with cognitive ability. Mol. Psychiatry 9(6) , 582–586 (2004).
- Mannelli P , PatkarA, RozenS, MatsonW, KrishnanR, Kaddurah-DaoukR. Opioid use affects antioxidant activity and purine metabolism: preliminary results. Hum. Psychopharmacol.24(8) , 666–675 (2009).
- Bu Q , YangY, YanG et al. Proteomic analysis of the nucleus accumbens in rhesus monkeys of morphine dependence and withdrawal intervention. J. Proteomics 75(4) , 1330–1342 (2012).